ABCDx has established multi-parametric panels which have the potential to transform the monitoring of patients, offering more rapid and specific decision making diagnosis to a much wider range of health care sites, including point-of-care, in the following areas:
Mild traumatic brain injury (Factsheet mTBI)
- Brain injuries have a high incidence worldwide. In particular mild traumatic brain injury (mTBI) is responsible for high health cost. In contrast to severe TBI, mTBI is not obvious to detect and thus usually a computer tomography (CT) scan is performed before significant brain injury can be ruled in or out.
- The use of biomarkers has been proposed as a means to reduce the amount of unnecessary CT scans.
- ABCDx TBI Biomarker panels has the potential of:
- Avoiding unnecessary CT scans.
- Predicting patient severity for selective treatment.
- Evaluating treatment efficacy.
Earlier identification of risk of post-stroke infections and other complications (Factsheet _ complications)
- According to the latest WHO statistics, stroke is the leading cause of severe morbidity and the second overall cause of mortality worldwide. Infection is the most common post-stroke complication worsening patients’ outcomes and mortality. Early initiation of antibiotic treatment is recommended, therefore, if a bacterial infection is present. The clinical symptoms of infections are unspecific. Further diagnostic work-ups are essential for a correct diagnosis. However, although preventive antibiotic therapy is safe, the likelihood of boosting antibiotic resistance in bacteria needs to be taken into account and prophylactic use of antibiotics is unpopular in the medical community. Moreover, recent clinical trials using prophylactic antibiotics for all stroke patients have failed (PASS & STROKE-INF).
- ABCDx biomarker panel offers the potential of a more tailored approach to preventive antibiotic therapy – using blood biomarkers that identify patients at a high risk of post-stroke infections –reducing this risk and increasing the efficacy of antibiotic therapy by allowing treatments to be implemented more rapidly on patients at risk.
- Thus, identification of novel blood biomarkers that could accurately predict post-stroke infections earlier and allow the optimal prevention or treatment strategy to be chosen rapidly would, therefore, represent a significant step forward and opens the door to novel means of post-stroke infection detection and treatment, and identifying new diagnostic and prognostic strategies.
- Based on current cohort studies, ABCDx believes that infection can be predicted / diagnosed 2-3 days earlier using its IP, including at admission for half of the patients. We anticipate the ABCDx panel to fit into the routine daily monitoring of Stroke Units and ICU patients following stroke.
Differentiation between ischemic and hemorrhagic stroke (Factsheet stroke)
- Stroke remains one of the most important neurological affection. It represents one of the main leading cause of preventable death worldwide. The two main subtypes of stroke are ischemic stroke (IS) and intracerebral hemorrhage stroke (ICH).
- An accurate differentiation of both subtypes is critical during acute phase to prescribe the most suitable treatment protocol, which is specific and widely different between IS and ICH. Nowadays stroke subtype diagnosis is mainly based on brain imaging data by computerized tomography (CT) or magnetic resonance imaging (MRI). Unfortunately, in spite of being highly sensitive, MRI and CT scans are rarely available, cannot be used repeatedly in primary hospital due to the lack of resources
- A wide-available rapid biochemical test would add advantages in the pre-hospital triage and management of stroke patients, allowing to begin reperfusion therapies (i.e. tPA treatment) at the ambulance and therefore improving enormously the rates of recovery of ischemic stroke patients.
- ABCDx has identified a combination of biomarkers highly efficient to achieve a rapid, accurate biochemical diagnosis of IS versus ICH in the first hours from symptoms onset, offering more rapid and specific decision making diagnosis to a much wider range of health care sites, including point-of-care.